Your browser doesn't support javascript.
siRNA Therapeutics against Respiratory Viral Infections-What Have We Learned for Potential COVID-19 Therapies?
Mehta, Aditi; Michler, Thomas; Merkel, Olivia M.
  • Mehta A; Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universität München, Butenandtstraße 5, Munich, 81377, Germany.
  • Michler T; Institute of Virology, Technische Universität München, Trogerstr. 30, Munich, 81675, Germany.
  • Merkel OM; Department of Pharmacy, Pharmaceutical Technology and Biopharmaceutics, Ludwig-Maximilians-Universität München, Butenandtstraße 5, Munich, 81377, Germany.
Adv Healthc Mater ; 10(7): e2001650, 2021 04.
Article in English | MEDLINE | ID: covidwho-1051192
ABSTRACT
Acute viral respiratory tract infections (AVRIs) are a major burden on human health and global economy and amongst the top five causes of death worldwide resulting in an estimated 3.9 million lives lost every year. In addition, new emerging respiratory viruses regularly cause outbreaks such as SARS-CoV-1 in 2003, the "Swine flu" in 2009, or most importantly the ongoing SARS-CoV-2 pandemic, which intensely impact global health, social life, and economy. Despite the prevalence of AVRIs and an urgent need, no vaccines-except for influenza-or effective treatments were available at the beginning of the COVID-19 pandemic. However, the innate RNAi pathway offers the ability to develop nucleic acid-based antiviral drugs. siRNA sequences against conserved, essential regions of the viral genome can prevent viral replication. In addition, viral infection can be averted prophylactically by silencing host genes essential for host-viral interactions. Unfortunately, delivering siRNAs to their target cells and intracellular site of action remains the principle hurdle toward their therapeutic use. Currently, siRNA formulations and chemical modifications are evaluated for their delivery. This progress report discusses the selection of antiviral siRNA sequences, delivery techniques to the infection sites, and provides an overview of antiviral siRNAs against respiratory viruses.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Respiratory Tract Infections / Virus Diseases / RNA, Small Interfering / COVID-19 Drug Treatment Type of study: Experimental Studies / Observational study Topics: Vaccines Limits: Humans Language: English Journal: Adv Healthc Mater Year: 2021 Document Type: Article Affiliation country: Adhm.202001650

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Respiratory Tract Infections / Virus Diseases / RNA, Small Interfering / COVID-19 Drug Treatment Type of study: Experimental Studies / Observational study Topics: Vaccines Limits: Humans Language: English Journal: Adv Healthc Mater Year: 2021 Document Type: Article Affiliation country: Adhm.202001650